Suppr超能文献

氨甲环酸治疗蛛网膜下腔出血:系统评价和荟萃分析。

Tranexamic acid for subarachnoid hemorrhage: A systematic review and meta-analysis.

机构信息

Department of Neurosurgery, Chongqing General Hospital, University of Chinese Academy of Sciences.China.

Department of Neurology, Central Hospital of Jiangjin District, Chongqing, China.

出版信息

Am J Emerg Med. 2021 Dec;50:748-752. doi: 10.1016/j.ajem.2021.09.047. Epub 2021 Sep 22.

Abstract

BACKGROUND

The efficacy of tranexamic acid for subarachnoid hemorrhage remains controversial. Thus, we conduct this meta-analysis to explore the efficacy of tranexamic acid for subarachnoid hemorrhage.

METHODS

PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of tranexamic acid on subarachnoid hemorrhage were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. This meta-analysis was performed using the random-effect model.

RESULTS

Five RCTs and 2359 patients were included in the meta-analysis. Overall, compared with control intervention for subarachnoid hemorrhage, tranexamic acid was associated with significantly reduced risk of rebleeding (Odd ratio [OR] =0.62; 95% confidence interval [CI] =0.41 to 0.93; P = 0.02), but had no influence on mortality (OR = 0.94; 95% CI = 0.75 to 1.18; P = 0.61), poor outcome (OR = 0.95; 95% CI = 0.61 to 1.48; P = 0.82), hydrocephalus (OR = 1.17; 95% CI = 0.94 to 1.46; P = 0.17) or delayed cerebral ischemia (OR = 1.26; 95% CI = 0.78 to 2.04; P = 0.34).

CONCLUSIONS

Tranexamic acid may be effective to reduce the risk of rebleeding in patients with subarachnoid hemorrhage.

摘要

背景

氨甲环酸治疗蛛网膜下腔出血的疗效仍存在争议。因此,我们进行了这项 meta 分析,以探讨氨甲环酸治疗蛛网膜下腔出血的疗效。

方法

系统检索了 PubMed、EMbase、Web of science、EBSCO 和 Cochrane 图书馆数据库。纳入评估氨甲环酸对蛛网膜下腔出血影响的随机对照试验(RCT)。两位研究者独立搜索文章、提取数据并评估纳入研究的质量。使用随机效应模型进行 meta 分析。

结果

共纳入 5 项 RCT 和 2359 例患者。总体而言,与蛛网膜下腔出血的对照干预相比,氨甲环酸与再出血风险显著降低相关(比值比 [OR] =0.62;95%置信区间 [CI] =0.41 至 0.93;P =0.02),但对死亡率(OR =0.94;95% CI =0.75 至 1.18;P =0.61)、不良结局(OR =0.95;95% CI =0.61 至 1.48;P =0.82)、脑积水(OR =1.17;95% CI =0.94 至 1.46;P =0.17)或迟发性脑缺血(OR =1.26;95% CI =0.78 至 2.04;P =0.34)无影响。

结论

氨甲环酸可能有助于降低蛛网膜下腔出血患者再出血的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验